Apart from chemotherapy regimens, novel targeted therapies such as phosphoinositide 3‐kinase (PI3K)‐targeted therapy may be effective in the treatment of patients with CRC5 and the glycogen synthase kinase 3 beta (GSK3β) mediates cell activities via the PI3K/AKT signalling pathway,6 implying the regulatory role of GSK3β in CRC. Here, GSK3B is linked to colorectal carcinoma.